Safety of Chronic Obstructive Pulmonary Disease Medications: A Primary Care Perspective

References

• . Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance–United States, 1971–2000. MMWR Surveill Summ. 2002;51(6):1–16
   Google Scholar
• . World Health Organization. Chronic obstructive pulmonary disease. Fact sheet No. 315. February 2011. http://www.who.int/mediacentre/factsheets/fs315/en. Accessed March 16, 2011
   Google Scholar
• . World Health Organization. World Health Statistics 2008. http://www.who.int/whosis/whostat/EN_WHS08_Full.pdf. Accessed March 16, 2011
   Google Scholar
• . Miniño AM, Xu J, Kochanek KD. Deaths: preliminary data for 2008. Natl Vital Stat Rep. 2010;59(2):1–71
   PubMedGoogle Scholar
• . Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–946
   PubMed Web of Science ®Google Scholar
• . Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. December 2010. http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=989. Accessed March 16, 2011
   Google Scholar
• . Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996;312(7040):1215–1218
   PubMed Web of Science ®Google Scholar
• . Gluud LL. Bias in clinical intervention research. Am J Epidemiol. 2006;163(6):493–501
   PubMed Web of Science ®Google Scholar
• . Hannan EL. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovasc Interv. 2008;1(3):211–217
   PubMed Web of Science ®Google Scholar
• . Hartling L, McAlister FA, Rowe BH, Ezekowitz J, Friesen C, Klassen TP. Challenges in systematic reviews of therapeutic devices and procedures. Ann Intern Med. 2005;142(12 pt 2):1100–1111
   PubMedGoogle Scholar
• . Mann CJ. Observational research methods. Research design II: cohort, cross sectional, and case-control studies. Emerg Med J. 2003;20(1):54–60
   PubMed Web of Science ®Google Scholar
• . National Health and Medical Research Council. How to use the evidence: assessment and application of scientific evidence. Handbook series on preparing clinical practice guidelines. February 2000. http://www.nhmrc.gov.au/_files_nhmrc/file/publications/synopses/cp69.pdf. Accessed March 16, 2011
   Google Scholar
• . Weingart SN, Gandhi TK, Seger AC,. Patient-reported medication symptoms in primary care. Arch Intern Med. 2005;165(2):234–240
   PubMedGoogle Scholar
• . Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: the importance of reporting suspected reactions. Arch Intern Med. 2005;165(12):1363–1369
   PubMed Web of Science ®Google Scholar
• . Li AP. An integrated, multidisciplinary approach for drug safety assessment. Drug Discov Today. 2004;9(16):687–693
   PubMed Web of Science ®Google Scholar
• . Li AP. A comprehensive approach for drug safety assessment. Chem Biol Interact. 2004;150(1):27–33
   PubMedGoogle Scholar
• . Roy PD, Majumder M, Roy B. Pharmacogenomics of anti-TB drugs-related hepatotoxicity. Pharmacogenomics. 2008;9(3):311–321
   PubMed Web of Science ®Google Scholar
• . Pavia D. Efficacy and safety of inhalation therapy in chronic obstructive pulmonary disease and asthma. Respirology. 1997;2( suppl 1): S5–S10
   Google Scholar
• . Gómez-Moreno G, Guardia J, Cutando A. Interaction of paracetamol in chronic alcoholic patients. Importance for odontologists. Med Oral Patol Oral Cir Bucal. 2008;13(4):E235–E238
   Google Scholar
• . Gupta P, O'Mahony MS. Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing. Drugs Aging. 2008;25(5):415–443
   PubMed Web of Science ®Google Scholar
• . Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of β-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125(6):2309–2321
   PubMed Web of Science ®Google Scholar
• . Giembycz MA, Newton R. Beyond the dogma: novel β2-adrenoceptor signalling in the airways. Eur Respir J. 2006;27(6):1286–1306
   PubMedGoogle Scholar
• . Rossi A, Khirani S, Cazzola M. Long-acting β2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety. Int J Chron Obstruct Pulmon Dis. 2008;3(4):521–529
   PubMedGoogle Scholar
• . Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1):15–26
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. Advair Diskus, Advair HFA, Brovana, Foradil, Perforomist, Serevent Diskus, and Symbicort information (long acting beta agonists). July 29, 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm108111.htm. Accessed March 16, 2011
   Google Scholar
• . US Food and Drug Administration. FDA Drug Safety Communication: New safety requirements for long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs). February 22, 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200776.htm. Accessed March 16, 2011
   Google Scholar
• . Calverley PM, Anderson JA, Celli B,; TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789
   PubMed Web of Science ®Google Scholar
• . Rodrigo GJ, Nannini LJ, Rodríguez-Roisin R. Safety of long-acting β-agonists in stable COPD: a systematic review. Chest. 2008;133(5):1079–1087
   PubMed Web of Science ®Google Scholar
• . Hui CK, Chung KF. Indacaterol: pharmacologic profile, efficacy and safety in the treatment of adults with COPD. Expert Rev Respir Med. 2011;5(1):9–16
   PubMed Web of Science ®Google Scholar
• . Kesten S, Celli B, Decramer M, Leimer I, Tashkin D. Tiotropium HandiHaler in the treatment of COPD: a safety review. Int J Chron Obstruct Pulmon Dis. 2009;4:397–409
   PubMedGoogle Scholar
• . Anthonisen NR, Connett JE, Enright PL, Manfreda J; Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002;166(3):333–339
   PubMed Web of Science ®Google Scholar
• . Lanes S, Golisch W, Mikl J. Ipratropium and Lung Health Study. Am J Respir Crit Care Med. 2003;167(5):801
   PubMed Web of Science ®Google Scholar
• . Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439–1450
   PubMed Web of Science ®Google Scholar
• . Tashkin DP, Celli B, Senn S,; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554
   PubMed Web of Science ®Google Scholar
• . Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010;137(1):20–30
   PubMed Web of Science ®Google Scholar
• . Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc. 2005;2(4):334–339
   PubMedGoogle Scholar
• . Barr RG, Rowe BH, Camargo CA Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. BMJ. 2003;327(7416):643
   PubMed Web of Science ®Google Scholar
• . Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008;149(6):380–390
   PubMed Web of Science ®Google Scholar
• . Ohta K, Fukuchi Y, Grouse L,. A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. Respir Med. 2004;98(10):1016–1024
   PubMedGoogle Scholar
• . Baid SK, Nieman LK. Therapeutic doses of glucocorticoids: implications for oral medicine. Oral Dis. 2006;12(5):436–442
   PubMedGoogle Scholar
• . Decramer M, de Bock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153(6 pt 1):1958–1964
   PubMedGoogle Scholar
• . Souverein PC, Berard A, Van Staa TP,. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90(8):859–865
   PubMedGoogle Scholar
• . Celli BR. Update on the management of COPD. Chest. 2008;133(6):1451–1462
   PubMed Web of Science ®Google Scholar
• . Crim C, Calverley PM, Anderson JA,. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009;34(3):641–647
   PubMed Web of Science ®Google Scholar
• . Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbations. Respir Med. 2008;102(8):1099–1108
   PubMed Web of Science ®Google Scholar
• . Hubbard RB, Smith CJ, Smeeth L, Harrison TW, Tattersfield AE. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med. 2002;166(12 pt 1):1563–1566
   PubMedGoogle Scholar
• . Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(20):2407–2416
   PubMed Web of Science ®Google Scholar
• . Singh S, Loke YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr Opin Pulm Med. 2010;16(2):118–122
   PubMed Web of Science ®Google Scholar
• . Mortimer KJ, Harrison TW, Tattersfield AE. Effects of inhaled corticosteroids on bone. Ann Allergy Asthma Immunol. 2005;94(1):15–21
   PubMedGoogle Scholar